Statins use and risk of mortality in patient with Clostridium difficile infection

Clinical Microbiology and Infection

Volumn 20, Issue 10, 2014, Pages 1061-1066

  Saliba, W ^a,b,c   Barnett Griness, O ^a,b   Elias, M ^c   Rennert, G ^a,b  

^a CLALIT HEALTH SERVICES   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c HAEMEK MEDICAL CENTER   (Israel)

Author keywords

Aspirin; Clostridium difficile; Mortality; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTIINFECTIVE AGENT;

AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; EPIDEMIOLOGY; FACTUAL DATABASE; PEPTOCLOSTRIDIUM DIFFICILE; VERY ELDERLY;

CLOSTRIDIUM DIFFICILE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASPIRIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISRAEL; MALE;

EID: 84913611881     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12672     Document Type: Article

References (24)

1. Janka J, O'Grady NP. Clostridium difficile infection: current perspectives. Curr Opin Crit Care 2009; 15: 149-153.
2. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-262.
3. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145: 758-764.
4. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008; 359: 1932-1940.
5. Mitchell BG, Gardner A. Mortality and Clostridium difficile infection: a review. Antimicrob Resist Infect Control 2012; 1: 20. doi:10.1186/2047-2994-1-20.
6. Hensgens MP, Goorhuis A, Dekkers OM, van Benthem BH, Kuijper EJ. All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin Infect Dis 2013; 56: 1108-1116.
7. Wenisch JM, Schmid D, Tucek G et al. A prospective cohort study on hospital mortality due to Clostridium difficile infection. Infection 2012; 40: 479-484.
8. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4: 977-987.
9. Björkhem-Bergman L, Bergman P, Andersson J, Lindh JD. Statin treatment and mortality in bacterial infections-a systematic review and meta-analysis. PLoS One 2010; 5: e10702.
10. Nseir W, Bishara J, Mograbi J et al. Do statins protect against the development of Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 2013; 68: 1889-1893.
11. Motzkus-Feagans CA, Pakyz A, Polk R, Gambassi G, Lapane KL. Statin use and the risk of Clostridium difficile in academic medical centres. Gut 2012; 61: 1538-1542.
12. Rothberg MB, Bigelow C, Pekow PS, Lindenauer PK. Association between statins given in hospital and mortality in pneumonia patients. J Gen Intern Med 2012; 27: 280-286.
13. Nseir W, Mograbi J, Abu-Elheja O, Bishara J, Assy N. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection 2012; 40: 41-48.
14. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008; 61: 774-785.
15. Al Harbi SA, Tamim HM, Arabi YM. Association between statin therapy and outcomes in critically ill patients: a nested cohort study. BMC Clin Pharmacol 2011; 11: 12.
16. Tleyjeh IM, Kashour T, Hakim FA et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 1658-1667.
17. Saliba W, Barnett O, Rennert HS, Rennert G. The risk of all-cause mortality is inversely related to serum 25(OH)D levels. J Clin Endocrinol Metab 2012; 97: 2792-2798.
18. Saliba W, Barnett O, Rennert HS, Lavi I, Rennert G. The relationship between serum 25(OH)D and parathyroid hormone levels. Am J Med 2011; 124: 1165-1170.
19. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 2011; 26: 546-5450.
20. Simpson SH, Eurich DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15.
21. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 177-186.
22. Park SW, Choi AR, Lee HJ et al. The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther 2013; 38: 619-627.
23. Hausding M, Witteck A, Rodriguez-Pascual F, von Eichel-Streiber C, Förstermann U, Kleinert H. Inhibition of small G proteins of the rho family by statins or Clostridium difficile toxin B enhances cytokine-mediated induction of NO synthase II. Br J Pharmacol 2000; 131: 553-561.
24. Shivashankar R, Khanna S, Kammer PP et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11: 1466-1471.